Oral Colchicine in Argentina to Prevent Restenosis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 410 participants.

Also called NCT04382443

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 410 participants (enrolled count) (from the registry)
Sponsor
Centro de estudios en Cardiologia Intervencionista (from the registry)
Registry
  • NCT NCT04382443
Main results
  • Randomized comparison between bare-metal stent plus colchicine versus drug-eluting stent alone in prevention of clinical adverse events after percutaneous coronary intervention Future cardiology, 2021-07 DOI, PubMed 33174761

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Argentina (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04382443. Randomized; no masking; primary purpose treatment. Start 2020-03-12 (actual); primary completion 2022-04-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Oral Colchicine in Argentina to Prevent Restenosis
Acronym
ORCA
Condition
Restenosis of Coronary Artery Stent
Condition
Atherosclerosis
Condition
Acute Coronary Syndrome
Intervention (Drug)
Colchicine
Lead sponsor
Centro de estudios en Cardiologia Intervencionista (class: other)

Record details

Record id
cardio:ct-nct04382443
Content hash
0009c918d21c8a42f87b6a4405f59fbf3b4d6a6cba715e0354b771e3d60f6112